Your Friendly Neighborhood Authority Community
China’s National Medical Products Administration is arguably more active than regulatory agencies in many nations in advancing guidance for AI in medical technology, but Chang-Hong Whitney, President/CEO of Whitney Consulting Ltd., told BioWorld that the premarket review process still carries some unpredictability.
BioWorld MedTech Regulatory Artificial intelligence Asia-Pacific China NMPA PMA
Content Curated Originally From Here
Click here to get the deets! (oh, and did I mention... it's free?)
